

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $93.88
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 12, 26 |
| Leerink Partners |
| maintain |
| Outperform |
| Outperform |
| Sep 3, 26 | UBS | maintain | Buy | Buy |
| Aug 19, 26 | Argus Research | maintain | Buy | Buy |
| Aug 12, 26 | JP Morgan | maintain | Overweight | Overweight |
| Aug 6, 26 | UBS | maintain | Buy | Buy |
| Aug 6, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 6, 26 | Evercore ISI Group | maintain | Outperform | Outperform |
| Jul 24, 26 | UBS | maintain | Buy | Buy |
| Jul 14, 26 | Truist Securities | maintain | Buy | Buy |
Stock news · updated daily
CVS Health's Aetna streamlines prior authorizations, approves more than 95% of eligible requests within 24 hours and expands bundled approvals to speed access to care.
New locations in Charlestown, Beverly and Swampscott expand access to convenient, affordable health care services Charlestown marks first MinuteClinic location in Boston WOONSOCKET, R.I., Oct. 20, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that MinuteClinic ®, the medical clinic inside select CVS Pharmacy® locations, has opened three new locations in Charlestown, Beverly and Swampscott, to help increase access to health care services for patients in those communities.
Retirement planning gets harder when healthcare coverage becomes a moving target. A familiar insurance card can mean access to trusted doctors, predictable prescription costs, and benefits that help stretch a fixed income.
SteelPeak Wealth LLC increased its stake in shares of CVS Health Corporation (NYSE: CVS) by 1,168.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,410 shares of the pharmacy operator's stock after buying an additional 28,013 shares
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The latest trading day saw CVS Health (CVS) settling at $92.17, representing a +1.97% change from its previous close.
New research study will explore the realities and opportunities of midlife and inform an upcoming documentary WOONSOCKET, R.I., Oct 15, 2026 /PRNewswire/ -- CVS Health ® (NYSE: CVS) today announced a new collaboration with The Midlife Collective, a media company and community platform dedicated to changing the cultural conversation around women and aging.
CVS Health outpaces Alignment Healthcare with stronger returns, rising earnings estimates and a lower valuation as Aetna???s turnaround gains traction.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 1.85 | 2.58 | Beat 39.5% | $106.1B |
| May 6, 2026 | 2.18 | 2.57 | Beat 17.9% | $100.4B |
| Feb 10, 2026 | 1.00 | 1.09 | Beat 9.0% | $105.7B |
| Oct 29, 2025 | 1.37 | 1.60 | Beat 16.8% | $102.9B |
| Jul 31, 2025 | 1.46 | 1.81 | Beat 24.0% | $98.92B |
| May 1, 2025 | 1.70 | 2.25 | Beat 32.4% | $94.59B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Aug 17, 2026 | 2026-08-17 16:19:58 | View |
| SC 13G/A | Aug 13, 2026 | 2026-08-13 16:34:36 | View |
| 13F-HR | Aug 6, 2026 | 2026-08-06 16:39:10 | View |
| 10-Q | Aug 5, 2026 | 2026-08-05 06:33:43 | View |
| 8-K | Aug 5, 2026 | 2026-08-05 06:32:06 | View |
| 4 | Jun 29, 2026 | 2026-06-29 15:11:55 | View |
| 11-K | Jun 23, 2026 | 2026-06-23 16:59:46 | View |
| 4 | Jun 1, 2026 | 2026-06-01 17:02:36 | View |
| 4 | Jun 1, 2026 | 2026-06-01 17:00:41 | View |
| 4 | May 22, 2026 | 2026-05-22 17:39:40 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | CVS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 24.5x | 25.3x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 11.7x | EPS est. 8.02 | Discount |
| Price / Book | 1.5x | 1.4x | In line |
| Price / Sales | 0.3x | 0.3x | In line |
| EV / EBITDA | 13.8x | 12.8x | In line |
| Return on equity | 6.4% | — | Weak |
| Gross margin | 14.2% | 15.5% | In line |
| Debt / Equity | 0.96 | 1.08 | Moderate |
| Piotroski / Altman Z | 7/9 | Z 2.48 | Grey zone |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 26, 26 | Clark James David | officer: SVP, Cont & Chief Acct Officer | F-InKind | 454 @ $90.98 | $41.30K |
| May 31, 26 | Newman Brian | officer: EVP, Chief Financial Officer | F-InKind | 2,478 @ $90.98 | $225.4K |
| May 31, 26 | Compton-Phillips Amy | officer: EVP, Chief Medical Officer | F-InKind | 7,618 @ $90.98 | $693.1K |
| May 20, 26 | Aguirre Fernando | director | D-Return | 30,437 @ $93.78 | $2.85M |
| May 21, 26 | Aguirre Fernando | director | D-Return | 1,563 @ $93.50 | $146.1K |
| May 19, 26 | Robbins Larry | director | S-Sale | 1,983,387 @ $94.45 | $187.3M |
| May 19, 26 | Robbins Larry | director | S-Sale | 151 @ $95.18 | $14.37K |
| May 20, 26 | Robbins Larry | director | S-Sale | 797,628 @ $93.48 | $74.56M |
FY2025 · 10-K disclosure
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-21
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 60.87 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 92.79 | Oscillator | Sell |
| Williams %R (14) | -12.79 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.49 (Hist 1.14) | Oscillator | Strong Buy |
| Average Directional Index (14) | 24.73 (+DI 31.4 / -DI 19.9) | Trend | Buy |
| EMA 20 | 90.44 | MA | Strong Buy |
| SMA 20 | 88.69 | MA | Strong Buy |
| EMA 50 | 91.93 | MA | Buy |
| SMA 50 | 91.66 | MA | Buy |
| SMA 200 | 88.39 | MA | Strong Buy |